SDSU Scientists Develop First Live and Killed Vaccine Candidates Against Avian Metapneumovirus Threat

Breakthrough Could Transform Control of a Respiratory Disease Costing North American Poultry Producers Millions of Dollars Annually

Brookings, South Dakota, June 10, 2026 — Researchers at South Dakota State University’s Animal Disease Research and Diagnostic Laboratory (ADRDL) have announced a significant breakthrough in the fight against Avian Metapneumovirus (aMPV), unveiling what could become the first successful live and killed vaccine candidates developed specifically against the rapidly emerging U.S. strain of Avian Metapneumovirus Subtype B.

The announcement marks a major milestone in poultry disease control and could provide the industry with its first targeted tool to combat a pathogen that has spread rapidly through commercial turkey and chicken operations across North America, causing substantial economic losses through respiratory disease, reduced productivity and increased mortality.

Scientists involved in the program confirmed that both vaccine candidates have demonstrated promising experimental results and are now advancing into field-evaluation studies designed to validate safety, efficacy and commercial performance under production conditions.

New Emerging Threat to U.S. Poultry Production

Avian Metapneumovirus has long been recognized as an economically important respiratory pathogen in poultry-producing regions around the world. However, the recent emergence and rapid spread of aMPV Subtype B in North American flocks has elevated concern throughout the poultry industry. The virus primarily affects:

• Turkeys

• Broiler chickens

• Breeder flocks

• Layer operations

In breeding and laying flocks, infections can also result in reduced egg production and deterioration in egg quality, further amplifying economic losses. Researchers at SDSU were among the first scientific groups to identify and characterize the emerging U.S. subtype, helping establish the pathogen as a major industry concern.

First Dual Vaccine Platform

The newly developed vaccine program incorporates two complementary approaches:

Live Attenuated Vaccine

The live vaccine candidate is designed to stimulate strong mucosal and cellular immunity, providing rapid protection against field infection. Potential advantages include:

• Early immune stimulation

• Reduced viral shedding

• Strong flock-level protection

• Compatibility with mass vaccination strategies

Inactivated (Killed) Vaccine

The killed vaccine candidate is intended primarily for breeder and long-lived production birds where durable immunity is critical. Benefits may include:

• Enhanced safety profile

• Booster vaccination compatibility

• Improved maternal antibody transfer

• Long-term protection in breeder populations

Industry experts note that successful deployment of both vaccine platforms could enable integrated vaccination programs tailored to different poultry production systems.

Field Trials to Evaluate Cross-Protection

One of the most important next steps involves determining whether the vaccine candidates can provide protection beyond the currently targeted Subtype B strain. Researchers have initiated field studies aimed at evaluating:

• Cross-protection against Avian Metapneumovirus Subtype A

• Duration of immunity

• Commercial flock performance

• Impact on viral shedding

• Protection under field-exposure conditions

Cross-protective immunity would significantly enhance the commercial value of the vaccines and potentially broaden their applicability across global poultry markets.

“If cross-protection is demonstrated, these vaccines could become relevant far beyond the current outbreak situation,” noted one poultry-health consultant familiar with the development.

The emergence of aMPV Subtype B has added another layer of risk for producers already managing challenges associated with avian influenza, infectious bronchitis, Newcastle disease and other respiratory pathogens.

Commercial Opportunity for Animal Health Companies

The successful development of a commercially viable vaccine could represent one of the most significant poultry-health product launches of the decade. Several factors support strong commercial potential – global poultry population exceeds:

• 30 billion broilers annually

• Hundreds of millions of layers

• Millions of commercial turkey birds

Competitive Landscape

The emergence of a commercially attractive aMPV vaccine opportunity is likely to attract interest from major poultry-health companies, including:

• Zoetis

• Boehringer Ingelheim Animal Health

• MSD Animal Health

• Elanco Animal Health

• Ceva Santé Animale

• Phibro Animal Health

Should SDSU’s technology continue to demonstrate positive field performance, licensing partnerships or commercialization agreements with established animal-health companies could become a logical next step.

Regulatory Pathway

Before commercial launch, the vaccine candidates must successfully complete:

1. Expanded field efficacy studies

2. Safety evaluations

3. Manufacturing validation

4. Regulatory review

5. Licensing approval

Depending on trial outcomes and regulatory timelines, industry experts believe initial commercial availability could potentially occur within the next several years.

Vaccine’s Global Outlook

The development of the first successful live and killed vaccine candidates targeting Avian Metapneumovirus Subtype B represents a potentially transformative advancement for poultry health.

For producers confronting a rapidly spreading respiratory pathogen, the breakthrough offers hope for a more effective and sustainable disease-control strategy. If forthcoming field trials confirm strong efficacy and cross-protection against additional strains, the SDSU program could lay the foundation for a new generation of respiratory disease vaccines and significantly reduce the economic burden of aMPV across global poultry production systems.

As field evaluations begin, the poultry industry will be watching closely to determine whether this scientific achievement can translate into a practical commercial solution for one of its newest and most costly disease threats.